BEDFORD, Mass.--(BUSINESS WIRE)-- Augmenix, Inc. is pleased to announce that the company’s leading product, SpaceOAR hydrogel, is now available to millions of American men covered under Medicare, ...
“Our phase 3 clinical trial previously demonstrated that SpaceOAR offers a significant benefit in reducing the risk of rectal complications and damage associated with radiation therapy in the ...
WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced FDA ...
SpaceOAR hydrogel is used to reduce common side effects that men experience after receiving prostate cancer radiotherapy. In addition to the new payers, SpaceOAR is reimbursed by six out of seven ...
First and only prostate cancer spacing device available for use in the U.S. clinically proven to preserve patient quality of life following radiation therapy BEDFORD, Mass.–(BUSINESS WIRE)–November 7, ...
Results published in the International Journal of Radiation Oncology Biology and Physics show on average no long-term declines in bowel and urinary quality of life for patients and 78% reduction in ...
The radiation oncology team at UH Seidman Cancer Center at UH Geauga Medical Center performed the first-ever prostate cancer treatment on April 3 using a newly approved device. The device, called ...
NEW YORK CITY, N.Y. (Ivanhoe Newswire) – This year, more than 162,000 men will be diagnosed with prostate cancer. Cancer treatment, while life-saving, can cause incontinence and erectile dysfunction.
DALLAS, March 14, 2018 /PRNewswire-PRWeb/ -- Urology Clinics of North Texas is pleased to announce the arrival of a new system for men choosing to undergo radiation therapy for prostate cancer. The ...
Texas Urology Specialists announces that physicians Dr. Ashley Ross and Dr. Mitchell Moskowitz are now using SpaceOAR hydrogel for men undergoing radiation therapy for prostate cancer. "The use of ...
WALTHAM, Mass.—April 2, 2015—Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced FDA clearance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results